Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma (KAPKEY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03469804
Recruitment Status : Recruiting
First Posted : March 19, 2018
Last Update Posted : October 21, 2019
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

Classic and endemic Kaposi's sarcoma (KS) are lymphangio-proliferations associated with human herpes virus 8 (HHV8), which treatment is poorly codified. Chemotherapies give at best 30-60% of transient responses. While interferon responses are frequent, this drug is often poorly tolerated in elderly patients. Therefore new therapies are needed. Classic KS represents an ideal model for evaluating new drugs since patients do not receive concomitant immunosuppressive regimens nor antiviral therapies.

Pembrolizumab, an anti-PD1 monoclonal antibody has recently been shown to improve survival in several solid tumors. In KS few data are available on the role of PD1-PD-L1 axis. A significant PD-L1 expression on HHV8-associated pleural effusion lymphomas and on KS samples have been recently reported. Our experience in classical and endemic KS supports the role of this pathway with expression of PD-L1 by subpopulations of T cells but also NK cells in peripheral blood cells from these patients and expression of PD-L1 by tumor cells in KS lesions.

In this study we will evaluate the benefit and safety profile of pembrolizumab in classic and endemic KS.


Condition or disease Intervention/treatment Phase
Kaposi Sarcoma Progression, Disease Drug: Pembrolizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 17 participants
Intervention Model: Single Group Assignment
Intervention Model Description: 2-stage phase II Simon's Optimal Design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Essai de Phase II Multicentrique évaluant le Pembrolizumab Dans le Traitement de la Maladie de Kaposi Classique ou endémique
Actual Study Start Date : July 1, 2018
Estimated Primary Completion Date : March 20, 2020
Estimated Study Completion Date : September 20, 2020


Arm Intervention/treatment
Experimental: Pembrolizumab
Pembrolizumab Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
Drug: Pembrolizumab
Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)




Primary Outcome Measures :
  1. Best Overall Response Rate (BORR) [ Time Frame: 6 months ]
    Best Overall Response Rate (BORR) defined by the occurrence of complete response or partial response following AIDS Clinical Trials Group (ACTG) criteria recorded from the start of treatment until 6 months or the beginning of any other specific systemic therapy for KS if it occurs before 6 months


Secondary Outcome Measures :
  1. Best overall response rate according to Physical Global Assessment (PGA) [ Time Frame: 6 months ]
    Best overall response rate according to Physical Global Assessment (PGA) score until 6 months or the beginning of any other specific systemic therapy for KS if it occurs before 6 months

  2. Response rate according to ACTG and PGA criteria [ Time Frame: 3 months ]
  3. Response rate according to ACTG and PGA criteria [ Time Frame: 6 months ]
  4. Response rate on number of lesions [ Time Frame: 3 months ]
    Response rate on number of lesions and at best response as defined following ACTG criteria

  5. Response rate on number of lesions [ Time Frame: 6 months ]
    Response rate on number of lesions and at best response as defined following ACTG criteria

  6. Response rate on the size of target lesions [ Time Frame: 3 months ]
    Response rate on the size of target lesions and at best response as defined following ACTG criteria

  7. Response rate on the size of target lesions [ Time Frame: 6 months ]
    Response rate on the size of target lesions and at best response as defined following ACTG criteria

  8. Response rate on tumor infiltration of target lesions [ Time Frame: 3 months ]
    Response rate on tumor infiltration of target lesions and at best response as defined following ACTG criteria

  9. Response rate on tumor infiltration of target lesions [ Time Frame: 6 months ]
    Response rate on tumor infiltration of target lesions and at best response as defined following ACTG criteria

  10. Response rate on lymphedema [ Time Frame: 3 months ]
    Response rate on lymphedema (circumference, scale of 0 (absence) to 3 (painful or oozing)) at Month 3, Month 6 and at best response as defined following ACTG criteria

  11. Response rate on lymphedema [ Time Frame: 6 months ]
    Response rate on lymphedema (circumference, scale of 0 (absence) to 3 (painful or oozing)) at Month 3, Month 6 and at best response as defined following ACTG criteria

  12. Time to response [ Time Frame: 6 months ]
    Time to response defined as the time to first response recorded from the start of treatment

  13. Time to progression [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Classic or endemic histologically confirmed KS
  • Progressive disease
  • KS with more than 10 lesions or involving more than one limb segment or with involvement >3% body surface
  • KS with at least 4 lesions ≥5mm
  • KS with at least 1 other cutaneous tumor available for repeated pharmacodynamics evaluation and be willing to provide tissue from cutaneous biopsy of a tumor lesion
  • At least 4 weeks washout for all KS specific therapies including chemotherapy and immunotherapy
  • Provide written, informed consent prior to the performance of any study specific procedures
  • Be ≥ 18 years of age on day of signing informed consent.
  • Have a performance status of 0 or 1 on the ECOG Performance Scale.
  • Demonstrate adequate organ function:

Hematological : Absolute neutrophil count (ANC) ≥1,000/mm3, Platelets ≥100,000 / mm3, Hemoglobin ≥ 9 g/dL Renal: Calculated creatinine clearance ≥40 mL/min (using Modification of diet in renal disease (MDRD) formula) Hepatic: AST (SGOT) and ALT (SGPT) ≤ 2.5xULN, serum total bilirubin ≤ 1.5xULN OR direct bilirubin ≤ ULN for subjects with total bilirubin levels >1.5xULN.

  • Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication
  • Have a health insurance

Exclusion Criteria:

  • Has a known history of organ transplantation or HIV (HIV 1/2 antibodies detected at selection) Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  • Has KS with symptomatic visceral involvement unless no other therapeutic option is available Previously received treatments with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 antibody or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
  • Has a known history of active infectious hepatitis, type B (HBsAg detected) or C (HCV RNA detected) or active TB (Tuberculosis Bacillus).
  • Has an active infection requiring systemic therapy.
  • Has hypersensitivity to pembrolizumab or any of its excipients.
  • Has had a prior anti-cancer monoclonal antibody (mAb) within last 4 weeks or who has not recovered (i.e., > Grade 1 at selection) from adverse events due to agents administered more than 4 weeks earlier.
  • Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 3 weeks prior to study Day 1 or who has not recovered (i.e., > Grade 1 at selection) from adverse events due to a previously administered agent (Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study). (Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy).
  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with vitiligo, type I diabetes mellitus, hypothyroidism, psoriasis non requiring systemic treatment are permitted to enroll.
  • Has active non-infectious pneumonitis or known history of non-infectious pneumonitis that required steroids, severe pulmonary disease or hypoxia
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, or not willing to use adequate contraceptive methods from study Visit 1 throughout the study period up to 120 days after the last dose of study therapy.
  • Has received a live vaccine within 30 days prior to the first dose of trial treatment or while participating in the trial.
  • Is currently participating or has participated in a study of an investigational agent within 4 weeks of the first dose of treatment.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • Patient under guardianship or curators

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03469804


Contacts
Layout table for location contacts
Contact: Celeste LEBBE, MD PhD 142499590 ext +33 celeste.lebbe@aphp.fr
Contact: Matthieu RESCHE-RIGON, MD PhD 142499742 ext +33 matthieu.resche-rigon@univ-paris-diderot.fr

Locations
Layout table for location information
France
Saint-Louis Hospital Recruiting
Paris, France, 75010
Contact: Celeste Lebbe, MD PhD    142499590 ext +33    celeste.lebbe@aphp.fr   
Contact: laetitia Da Meda    142499392 ext +33    laetitia.da-meda@aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT03469804     History of Changes
Other Study ID Numbers: P160601
2016-003714-27 ( EudraCT Number )
First Posted: March 19, 2018    Key Record Dates
Last Update Posted: October 21, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma, Kaposi
Sarcoma
Disease Progression
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Disease Attributes
Pathologic Processes
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Neoplasms, Vascular Tissue
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents